ADAR1 Capital Management’s CytomX Therapeutics CTMX Stock Holding History

ADAR1 Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6M	Sell	3,365,118 -45,072	-1%	-$172K	0.58%	43
2026 Q1	$16M	Sell	3,410,190 -772,579	-18%	-$3.92M	0.94%	21
2025 Q4	$17.8M	Buy	4,182,769 +137,355	+3%	+$522K	1.31%	13
2025 Q3	$12.9M	Buy	4,045,414 +964,000	+31%	+$2.17M	1.21%	17
2025 Q2	$6.99M	Buy	3,081,414 +3,034,378	+6,451%	+$4.89M	1.07%	24
2025 Q1	$29.9K	Sell	47,036 -98,000	-68%	-$76K	0.01%	188
2024 Q4	$149K	Sell	145,036 -758,923	-84%	-$816K	0.03%	169
2024 Q3	$1.07M	Buy	903,959 +331,789	+58%	+$421K	0.17%	69
2024 Q2	$698K	Buy	572,170 +417,170	+269%	+$830K	0.13%	81
2024 Q1	$338K	Buy	+155,000	New	+$286K	0.08%	98

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ADAR1 Capital Management's CTMX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its CytomX Therapeutics (CTMX) stake by 1.3% in Q2 2026, selling an estimated $172K and leaving 3,365,118 shares worth $12.6M. The position accounts for 0.58% of the portfolio, ranked #43.

ADAR1 Capital Management first reported a position in CTMX in Q1 2024 and has held it in 10 quarters since. The position peaked at $17.8M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

ADAR1 Capital Management held 3,365,118 shares of CytomX Therapeutics worth $12.6M as of Q2 2026.
ADAR1 Capital Management sold 45,072 CytomX Therapeutics shares in Q2 2026, an estimated $172K.
CytomX Therapeutics made up 0.58% of ADAR1 Capital Management's portfolio in Q2 2026, its #43 holding.
ADAR1 Capital Management first reported a position in CytomX Therapeutics in Q1 2024 and has held it in 10 quarters since.
ADAR1 Capital Management's CytomX Therapeutics position peaked at $17.8M in Q4 2025.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.